Cornerstone Robotics vs Mirador Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $200M oversubscribed (Nov 2025) backed by Hong Kong Investment Corporation and sovereign wealth funds. China NMPA-approved. UK colorectal/urologic clinical trial launched.
About
Cornerstone Robotics is a surgical robotics company whose Sentire Endoscopic Surgical System uses multiple robotic arms to enable minimally invasive surgery with enhanced dexterity beyond single-arm laparoscopic systems. The company raised $200 million in an oversubscribed round in November 2025, backed by the Hong Kong Investment Corporation and global sovereign wealth funds. Sentire has received China National Medical Products Administration (NMPA) approval and launched UK clinical trials for colorectal and urologic procedures in 2025, with 2026 as its international commercialization ramp year.
Raised $250M Series B (Jan 2026). $650M+ total raised. Mirador360 genetics-first platform. 10+ clinical readouts by end of 2027. Pipeline spans Crohn's, ulcerative colitis, RA, IPF.
About
Mirador Therapeutics is a precision immunology company with a genetics-first platform (Mirador360) that uses human genetic data to identify the most biologically validated targets and patient subpopulations for inflammatory and fibrotic diseases. The company closed a $250 million Series B in January 2026, bringing total funding above $650 million, with an ambitious pipeline targeting Crohn's disease, ulcerative colitis, rheumatoid arthritis, and idiopathic pulmonary fibrosis (IPF). Ten or more clinical readouts are expected by end of 2027.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.